These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26170677)

  • 1. Canagliflozin-induced pancreatitis: a rare side effect of a new drug.
    Chowdhary M; Kabbani AA; Chhabra A
    Ther Clin Risk Manag; 2015; 11():991-4. PubMed ID: 26170677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Side Effects: Empagliflozin-Related Acute Pancreatitis Case Report.
    Zeidan BS; Boadu C; Hernandez A; Frunzi J; Adetula I
    Cureus; 2020 Dec; 12(12):e12325. PubMed ID: 33520523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus.
    Srivali N; Thongprayoon C; Cheungpasitporn W; Ungprasert P
    J Basic Clin Pharm; 2015 Jun; 6(3):101-2. PubMed ID: 26229348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canagliflozin-Associated Acute Pancreatitis.
    Verma R
    Am J Ther; 2016; 23(3):e972-3. PubMed ID: 25187092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern.
    Gelaye A; Haidar A; Kassab C; Kazmi S; Sinha P
    Case Rep Crit Care; 2016; 2016():1656182. PubMed ID: 27088018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin review - safety and efficacy profile in patients with T2DM.
    Jakher H; Chang TI; Tan M; Mahaffey KW
    Diabetes Metab Syndr Obes; 2019; 12():209-215. PubMed ID: 30787627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Common Medication with an Uncommon Adverse Event: A Case of Doxycycline-induced Pancreatitis.
    Paulraj S; Ashok Kumar P; Subedi D
    Cureus; 2020 Apr; 12(4):e7496. PubMed ID: 32368428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin-associated diabetic ketoacidosis: a case report.
    Chai PR; Bonney C; Blohm E; Boyer EW; Babu KM
    Toxicol Commun; 2017; 1(1):2-5. PubMed ID: 29978156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin.
    Danford C; Chan P; Magill SB
    WMJ; 2016 Aug; 115(4):206-9. PubMed ID: 29099159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study.
    Rizvi SM; Shakil S; Biswas D; Shakil S; Shaikh S; Bagga P; Kamal MA
    CNS Neurol Disord Drug Targets; 2014 Apr; 13(3):447-51. PubMed ID: 24059302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.
    da Silva PN; da Conceição RA; do Couto Maia R; de Castro Barbosa ML
    Medchemcomm; 2018 Aug; 9(8):1273-1281. PubMed ID: 30151080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes.
    Hassani-Ardakania K; Lipman ML; Laporta D; Yu OHY
    Case Rep Endocrinol; 2019; 2019():8639629. PubMed ID: 31275667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.
    Turner J; Begum T; Smalligan RD
    J Investig Med High Impact Case Rep; 2016; 4(3):2324709616663231. PubMed ID: 27635409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypercalcemia secondary to excessive self-medication with antacids causing acute pancreatitis: a case report.
    Vassallo P; Green N; Courtney E
    Croat Med J; 2019 Feb; 60(1):42-45. PubMed ID: 30825277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug-induced pancreatitis].
    Shachar E; Scapa E
    Harefuah; 2009 Feb; 148(2):98-100, 139. PubMed ID: 19627037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
    Lamos EM; Hedrington M; Davis SN
    Expert Opin Drug Saf; 2019 Aug; 18(8):691-701. PubMed ID: 31150300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxycycline-induced pancreatitis: a rare finding.
    Wachira JK; Jensen CH; Rhone K
    S D Med; 2013 Jun; 66(6):227-9. PubMed ID: 23923680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.